Tirzepatide vs Cagrilintide

Two mechanisms, not two versions of one

Most head-to-head peptide comparisons pit two molecules from the same family against each other. This one does not. Tirzepatide and Cagrilintide are studied toward the same broad end — appetite and metabolic research — but they engage two distinct hormone systems. Tirzepatide works through the incretin axis, mimicking the gut hormones GIP and GLP-1. Cagrilintide works through amylin, a pancreatic hormone with its own dedicated receptors in the brainstem. Understanding that split is the whole point of putting them side by side: they are not rivals so much as representatives of two different routes to the same physiology, and researchers frequently study them together rather than in place of one another.

Tirzepatide: the dual incretin agonist

Tirzepatide (Eli Lilly, code LY3298176, marketed as Mounjaro and Zepbound) is a first-in-class dual agonist of the GIP and GLP-1 receptors — often called a "twincretin". It is a synthetic 39-amino-acid peptide of roughly 4,813 Da, carrying a C20 fatty-acid tail that promotes reversible albumin binding and gives it a terminal half-life of around five days, enough to support a once-weekly research schedule. The design idea is that GLP-1 and GIP act on overlapping but non-identical tissues — brain satiety circuits, pancreatic β-cells and adipose tissue — so co-activating both yields a larger metabolic signal than a selective GLP-1 agonist alone.

That thesis carried through into large trials: in the Phase 3 SURMOUNT-1 obesity programme Tirzepatide reached up to approximately 22.5% mean body-weight reduction, and in the SURPASS diabetes programme it outperformed selective GLP-1 agonism on glycaemic control. It is FDA-approved in those therapeutic settings, though the material supplied here is a research reagent only. For the full mechanism, trial data and pharmacokinetics, see the Tirzepatide knowledgebase profile, or go straight to buy Tirzepatide UK for research-grade material.

Cagrilintide: the amylin analogue

Cagrilintide (Novo Nordisk, code AM833) sits in a completely different class. It is a long-acting analogue of amylin — the neuroendocrine hormone co-secreted with insulin from pancreatic β-cells — and it is emphatically not an incretin. Rather than the GIP or GLP-1 receptors, it agonises the amylin receptors: heterodimers of the calcitonin receptor paired with RAMP proteins, giving the AMY₁, AMY₂ and AMY₃ subtypes. Its principal sites of action lie in the brainstem — the area postrema and dorsal vagal complex — where amylin signalling drives satiety and slows gastric emptying. A C20 fatty-diacid acylation extends its half-life to roughly seven to eight days, longer than Tirzepatide's, which conveniently matches the once-weekly cadence of its GLP-1 partner.

Cagrilintide's defining role is as the amylin arm of CagriSema, the combination with semaglutide 2.4 mg. In a Phase 1b trial that combination produced roughly 15.7% to 17.1% weight loss over 20 weeks versus about 9.8% for semaglutide alone, while Cagrilintide monotherapy dose-finding reported up to around 10.8% at the 4.5 mg dose over 26 weeks. It remains an investigational compound — the CagriSema combination reached Phase 3 in the REDEFINE obesity programme — and is supplied only as a research reagent. Full detail sits on the Cagrilintide knowledgebase profile; research material is available to buy Cagrilintide UK.

What the differences mean in a research context

The cleanest way to read this comparison is by receptor system. Tirzepatide is an incretin compound — it engages the gut-hormone receptors that GLP-1 and GIP act on. Cagrilintide is an amylin compound — it engages a receptor family the incretins never touch. That single distinction explains almost everything downstream. It is why the two are usually studied in combination rather than in a straight contest: because their satiety circuits only partially overlap, stacking an amylin analogue on top of an incretin is expected to add effect the incretin cannot supply on its own. CagriSema is exactly that logic applied to semaglutide, and the same rationale extends naturally to pairing amylin agonism with a dual agonist like Tirzepatide.

The secondary differences follow the same theme. Tirzepatide's ~5-day half-life and Cagrilintide's ~7–8-day half-life both support once-weekly work, but they sit either side of the same weekly rhythm — a practical convenience when the two are co-administered. On regulatory footing they diverge sharply: Tirzepatide carries a mature, FDA-approved dataset behind Mounjaro and Zepbound, whereas Cagrilintide is still investigational, with its pivotal evidence tied to the CagriSema programme rather than to monotherapy. And the headline effect sizes are not directly comparable — Tirzepatide's ~22.5% comes from a large Phase 3 obesity trial, while Cagrilintide's most striking figures come from combination studies, not the molecule acting alone.

For research purposes, then, the honest framing is not "which is stronger" but "which mechanism". A study designed around incretin biology reaches for Tirzepatide; one designed around amylin signalling, or around combination pharmacology, reaches for Cagrilintide. The interesting questions increasingly live at the intersection of the two.

The bottom line

Tirzepatide and Cagrilintide are not two flavours of the same drug — they are two different hormone systems put to the same research question. Tirzepatide is the dual GIP/GLP-1 incretin agonist with the mature, approved dataset; Cagrilintide is the long-acting amylin analogue whose value is clearest in combination. Choose by mechanism, not by league table. For research-grade material, see our dedicated pages to buy Tirzepatide UK and buy Cagrilintide UK, each ≥99% purity with a COA, and read the full Cagrilintide profile if the amylin route is where your work is heading.